Literature DB >> 33653991

Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson's disease.

Birgul Balci1, Burcin Aktar1,2, Sinan Buran2, Melike Tas2, Berril Donmez Colakoglu3.   

Abstract

The coronavirus disease 2019 pandemic has yielded containment measures with detrimental effects on the physical and mental health of the general population. The impacts of lockdown on clinical features in Parkinson's disease are not well known. We aimed to compare the physical activity, anxiety-depression levels between Parkinson's disease patients and controls during lockdown. Forty-five Parkinson's disease patients and 43 controls were evaluated with the Physical Activity Scale for the Elderly (PASE) and Hospital Anxiety and Depression Scale (HADS) via telephone interview. The patients' disease-related symptoms were worsened during lockdown though regular Parkinson's disease medication use. The PASE scores were low in both groups. The HADS scores of groups were below the cutoff point of anxiety-depression presence. Pandemic restrictions could lead to worsening of the motor and nonmotor symptoms in Parkinson's disease.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33653991      PMCID: PMC8103842          DOI: 10.1097/MRR.0000000000000460

Source DB:  PubMed          Journal:  Int J Rehabil Res        ISSN: 0342-5282            Impact factor:   1.832


Introduction

The coronavirus disease 2019 (COVID-19) is ongoing to spread around the world. The first COVID-19 case in Turkey was declared on 11 March 2020. To protect all citizens against the spread of the infection, the government of Turkey has implemented precautions involving closure of schools and universities, public rest and entertainment venues (restaurant/cafe, shopping malls, sports centers, etc.), interprovincial travel restrictions. It has been instructed that all subjects keep in self-isolation and stay at home. The Turkish Ministry of Interior was announced that all individuals aged 65 years and older were restricted from leaving their homes, travelling by public transport, walking around in parks and outdoors since 21 March 2020. The exact hours of curfew were 24 h/day. People living in their houses with gardens were only allowed to walk/work on their own gardens. These prohibitions were ended on 1 June 2020. No restrictions were imposed for individuals under the age of 65 years (The Turkish Ministry of Health, June 2020). The COVID-19 pandemic has yielded a health emergency causing unprecedented lifestyle changes due to infection rates and lockdown measures throughout the world [1]. The isolation precautions may pose risks to the physical activity levels (PALs) of individuals, while coping with stress during pandemic may worsen the mental health of people. We, therefore, aimed to examine the PALs, anxiety–depression severities of Parkinson’s disease patients and healthy individuals under lockdown conditions.

Methods

The study was approved by The Turkish Ministry of Health, and the Ethics Committee of Dokuz Eylul University (Protocol number: 5490-GOA; approval number: 2020/13-33). All procedures were performed in accordance with the Declaration of Helsinki principles. The study included patients with Parkinson’s disease and healthy individuals. Both Parkinson’s disease patients and age and sex-matched healthy subjects were the participants of a previous study that we had conducted to assess the association of PALs with postural instability in Parkinson’s disease patients comparing to healthy subjects [2]. The inclusion criteria for Parkinson’s disease participants were determined as a clinical diagnosis of idiopathic Parkinson’s disease according to the United Kingdom Parkinson’s Disease Society Brain Bank [3], ability to ambulate without assistance/walking aid, and regular Parkinson’s disease medication use. The exclusion criteria were the brain surgery history, presence of other neurological, musculoskeletal and cardiovascular diseases that negatively influence the PALs. The healthy subjects had no neurological, musculoskeletal, and cardiovascular diseases that negatively influence their PALs. A phone interview based on questionnaires about physical activity (PASE) and anxiety-depression (HADS) levels was done. Data were collected by two physiotherapists (S.B. and M.T.), 2 years and 1 year experienced in neurorehabilitation respectively. Before data collection, two investigators were trained in how to gather interview questions by focus group meeting. The participants were asked to reply all questions considering the time between 11 March (the declaration of the first COVID-19 case) and 1 June (the end of lockdown restrictions in Turkey) on 15–20 June 2020. The Physical Activity Scale for the Elderly (PASE) evaluates the leisure-time, household, and work-related activities during the previous 7 days [4]. Higher scores indicate greater physical activity. It is a valid and reliable questionnaire for elderly in Turkish population [5]. The Hospital Anxiety and Depression Scale (HADS) is a questionnaire screening anxiety–depression state among general outpatient clinic [6]. It comprises two subscales: anxiety (HADS-A) and depression (HADS-D). Higher scores indicate greater anxiety/depression severity [6,7]. For both subscales, the cutoff point to detect anxiety/depression is seven points [8]. It is a valid and reliable tool in Turkish [7]. All analyses were performed by using the IBM SPSS software. The Mann–Whitney U test was used to compare the medians of PASE and HADS between the groups. The significance level was set at P < 0.05.

Results

In total, 114 people (56 Parkinson’s disease patients and 58 healthy subjects) were enrolled in the previous study [2]. Twenty-six subjects were excluded from the current study due to unwillingness to participate (for healthy subjects n = 2), irregular Parkinson’s disease medication use (n = 4), unable to reach via phone calls (for Parkinson’s disease patients n = 7, for healthy subjects n = 13). Finally, 45 Parkinson’s disease patients and 43 controls were included with a response rate of 77.19%. Characteristic features of participants are presented in Table 1. Curfew for over 65 years was valid in 27 (60.0%) patients and 23 (53.5%) controls. None of the participants were diagnosed with the COVID-19.
Table 1

Participants’ characteristics

Parkinson’s diseasegroup (n = 45)Healthy control group(n = 43)P
Age (years)67.00 (60.00–73.50)66.00 (58.00–71.00)0.435a
Gender, female/male, n (%)15/30 (33.3/66.7)19/24 (44.2/55.8)0.382b
Parkinson’s disease duration (years)8.00 (5.00–10.00)N/AN/A
The COVID-19 related questions, n (%)
Living situation during lockdown
 Alone6 (13.3)6 (14.0)0.902c
 With partner22 (48.9)24 (55.8)
 With family14 (31.1)11 (25.6)
 Other3 (6.7)2 (4.7)
Housing situation during lockdown
 House14 (31.1)6 (14.0)0.075b
 Flat/apartment31 (68.9)37 (86.0)
Residential status during lockdown
 City center29 (64.4)36 (83.7)0.111c
 Outskirts13 (28.9)5 (11.6)
 Rural3 (6.7)2 (4.7)
Occupational status during lockdown
 Retired/not working34 (75.6)29 (67.4)0.107c
 Housewife9 (20.0)6 (14.0)
 Working2 (4.4)8 (18.6)
Regular exercise habit during lockdown
 No difference, I did  regular exercise as prepandemic6 (13.3)4 (9.3)0.353c
 I have no exercise   habits27 (60.0)21 (48.8)
 I did less exercise than   prepandemic12 (26.7)16 (37.2)
 I did more exercise   than prepandemic02 (4.7)
How was your physical activity level affected during the COVID-19 lockdown?
 No difference14 (31.1)12 (27.9)0.292c
 Decreased31 (68.9)28 (65.1)
 Increased03 (7.0)
How was the lockdown changed/affected your Parkinson’s disease/health*?
 Negatively affected31 (68.9)29 (67.4)1.000b
 No difference14 (31.1)14 (32.6)

Continuous variables were presented as median (interquartile range).

N/A, not applicable.

aStatistical significance was determined by Mann–Whitney U test.

bStatistical significance was determined by Chi-square test.

cStatistical significance was determined by Fisher’s Exact test.

*While Parkinson’s disease patients were asked to consider the disease specific changes, healthy subjects were asked to address the change in general health status.

Participants’ characteristics Continuous variables were presented as median (interquartile range). N/A, not applicable. aStatistical significance was determined by Mann–Whitney U test. bStatistical significance was determined by Chi-square test. cStatistical significance was determined by Fisher’s Exact test. *While Parkinson’s disease patients were asked to consider the disease specific changes, healthy subjects were asked to address the change in general health status. The worsening of motor and nonmotor symptoms during lockdown was reported by 31 (68.9%) patients. Twenty-two of 31 patients were 65 years and older, whereas 9 patients were younger than 65 years. The symptom that most frequently worsened was bradykinesia for patients ≥65 years and <65 years of age (Table 2). Also, two patients in group ≥65 years suffered from increased fatigue.
Table 2

The outcome of Parkinson’s disease-related symptoms during lockdown, n (%)

Parkinson’s disease group (n = 45)
≥ 65 years (n = 27)<65 years (n = 18)
WorseningNo differenceWorseningNo differenceP
Tremor (tremor of the extremity)7 (25.9)20 (74.1)4 (22.2)14 (77.8)1.000a
Dyskinesia4 (14.8)23 (85.2)3 (16.7)15 (83.3)1.000a
Bradykinesia (slowness of movements like turning in bed, rising of chair)15 (55.6)12 (44.4)7 (38.9)11 (61.1)0.273b
Rigidity*13 (48.1)14 (51.9)5 (27.8)13 (72.2)0.172b
Gait impairments (height of foot lift, stride length/speed, arm swing)12 (44.4)15 (55.6)6 (33.3)12 (66.7)0.456b
Freezing of gait6 (22.2)21 (77.8)1 (5.6)17 (94.4)0.215a
Balance problem10 (37.0)17 (63.0)5 (27.8)13 (72.2)0.519b
Cognitive impairment (paying attention, following conversations)6 (22.2)21 (77.8)1 (5.6)17 (94.4)0.215a
Sleep problems7 (25.9)20 (74.1)2 (11.1)16 (88.9)0.279a
Daytime sleepiness6 (22.2)21 (77.8)1 (5.6)17 (94.4)0.215a
Pain and other sensations (like aches, cramps and tingling)10 (37.0)17 (63.0)5 (27.8)13 (72.2)0.519b

*Stiffness complaint in the extremities was accepted as ‘rigidity’.

Statistical significance was determined by Fisher’s Exact test.

Statistical significance was determined by Chi-square test.

The outcome of Parkinson’s disease-related symptoms during lockdown, n (%) *Stiffness complaint in the extremities was accepted as ‘rigidity’. Statistical significance was determined by Fisher’s Exact test. Statistical significance was determined by Chi-square test. The PALs of patients and controls were low without a significant difference (P > 0.05). No participants had anxiety–depression (Table 3).
Table 3

The physical activity, anxiety–depression levels of groups during lockdown

Parkinson’s disease group (n = 45)Healthy control group (n = 43)ZPa
PASE
Leisure-time activities23.50 (7.63–34.85)27.09 (7.81–52.89)−0.5430.587
Household activities60.00 (25.00–103.00)60.00 (50.00–105.00)−0.1380.890
Work-related activities0.00 (0.00–0.00)0.00 (0.00–0.00)−0.5970.550
Total87.09 (57.63–130.95)92.78 (53.30–150.36)−0.4970.619
HADS
Anxiety4.00 (2.00–7.00)5.00 (1.00–8.00)−0.0290.977
Depression5.00 (2.50–7.00)4.00 (1.00–8.00)−0.6370.524

Variables were presented as median (interquartile range).

HADS, Hospital Anxiety and Depression Scale; PASE, Physical Activity Scale for the Elderly.

Statistical significance was determined using Mann–Whitney U test.

The physical activity, anxiety–depression levels of groups during lockdown Variables were presented as median (interquartile range). HADS, Hospital Anxiety and Depression Scale; PASE, Physical Activity Scale for the Elderly. Statistical significance was determined using Mann–Whitney U test.

Discussion

Our findings showed that the PALs were reduced in both groups, and anxiety–depression levels of groups were similar. In lockdown, Parkinson’s disease patients are in a serious threat due to physical inactivity [9]. According to our findings, the same danger of inactivity was valid for all people related to advancing age. However, two observations reported that Parkinson’s disease patients had worse anxiety and physical activity than controls during COVID-19 pandemic [9,10]. Mandatory lockdown in Turkey for all people aged 65 years and older may inhibit physical-habitual activities. Moreover, COVID-19 pandemic induced the exacerbation of disease-specific symptoms in Parkinson’s disease [11]. It has been stated that worsened symptoms were slowness, stiffness/rigidity, tremor, gait, freezing of gait, speech, easy fatigability, pain, sleep disorders, concentration, feeling stressed, anxiety–depression, constipation, and forgetfulness during the outbreak [12-16]. We found that Parkinson’s disease-related symptoms of patients were aggravated though regular Parkinson’s disease medication use. It may due to the stress resulting from pandemic [13], restriction of outdoor activities, social distancing [17], and staying away from other family members. It has become necessary to adapt exercise programs under home confinement conditions [11,12]. Because PA has a positive effect on physical and mental health [18], the general well-being is under great risk in lockdown conditions [19]. Anxiety–depression levels were similar in our groups. But these values were not ≥7 points to prove the presence of anxiety–depression. These findings may be related to the perception of health, the severity of disease, sociodemographical characteristics, environmental conditions (urban/rural lifestyle), and prepandemic social lifestyle. This study has some limitations. The Parkinson’s disease-related symptoms were not evaluated by the Unified Parkinson’s Disease Rating Scale, Hoehn and Yahr staging scale via phone interview. The feasibility of online and phone interviews of these instruments is controversial yet [20]. The information about physical activity and anxiety-depression levels was obtained with self-reported questionnaires via phone interview, which might increase the risk of bias and insufficient recall. Another limitation included our study method as a phone interview which was conducted by two investigators; however, they were well-trained for standardized data collection against bias risk.

Conclusion

Lockdown could lead to worsening of the motor and nonmotor symptoms in Parkinson’s disease related to physical inactivity.

Acknowledgements

We are grateful to all patients for participating in the study during this difficult period. The authors thank Mert Paldrak (Department of Industrial Engineering, Yasar University) for English editing. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. B.B. and B.A. are the first joint authorship.

Conflicts of interests

There are no conflicts of interest.
  19 in total

1.  Protecting and Improving the Lives of Older Adults in the COVID-19 Era.

Authors:  Edward Alan Miller
Journal:  J Aging Soc Policy       Date:  2020 Jul-Oct

2.  Does the postural stability of patients with Parkinson's disease affect the physical activity?

Authors:  Burcin Aktar; Berril Donmez Colakoglu; Birgul Balci
Journal:  Int J Rehabil Res       Date:  2020-03       Impact factor: 1.479

3.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

4.  Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life.

Authors:  Indu Subramanian; Joshua Farahnik; Laurie K Mischley
Journal:  NPJ Parkinsons Dis       Date:  2020-10-08

5.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

6.  Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic.

Authors:  Ali Shalash; Tamer Roushdy; Mohamed Essam; Mai Fathy; Noha L Dawood; Eman M Abushady; Hanan Elrassas; Asmaa Helmi; Eman Hamid
Journal:  Mov Disord       Date:  2020-06-07       Impact factor: 10.338

7.  Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic.

Authors:  Mehri Salari; Alireza Zali; Farzad Ashrafi; Masoud Etemadifar; Soumya Sharma; Nastaran Hajizadeh; Helia Ashourizadeh
Journal:  Mov Disord       Date:  2020-05-21       Impact factor: 10.338

8.  The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson's Disease.

Authors:  Anouk van der Heide; Marjan J Meinders; Bastiaan R Bloem; Rick C Helmich
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

9.  Impact of home confinement during COVID-19 pandemic on Parkinson's disease.

Authors:  Niraj Kumar; Ravi Gupta; Hrishikesh Kumar; Sahil Mehta; Roopa Rajan; Deva Kumar; Rukmini Mridula Kandadai; Soaham Desai; Pettarusp Wadia; Purba Basu; Banashree Mondal; Ankita Rawat; Sai Srilakshmi Meka; Bhushan Mishal; L K Prashanth; Achal Kumar Srivastava; Vinay Goyal
Journal:  Parkinsonism Relat Disord       Date:  2020-09-06       Impact factor: 4.891

Review 10.  The psychological impact of quarantine and how to reduce it: rapid review of the evidence.

Authors:  Samantha K Brooks; Rebecca K Webster; Louise E Smith; Lisa Woodland; Simon Wessely; Neil Greenberg; Gideon James Rubin
Journal:  Lancet       Date:  2020-02-26       Impact factor: 79.321

View more
  11 in total

Review 1.  Psychological outcomes of the COVID-19 pandemic in patients with Parkinson's disease: A systematic review.

Authors:  Fardin Nabizadeh; Zahrasadat Seyedalhosseini; Mohammad Balabandian; Mohammad Reza Rostami
Journal:  J Clin Neurosci       Date:  2022-06-28       Impact factor: 2.116

2.  The effects of Alzheimer's and Parkinson's disease on 28-day mortality of COVID-19.

Authors:  M Fathi; F Taghizadeh; H Mojtahedi; S Zargar Balaye Jame; N Markazi Moghaddam
Journal:  Rev Neurol (Paris)       Date:  2021-09-13       Impact factor: 4.313

3.  Social isolation, loneliness and mental health sequelae of the Covid-19 pandemic in Parkinson's disease.

Authors:  Bradley McDaniels; Indu Subramanian
Journal:  Int Rev Neurobiol       Date:  2022-04-23       Impact factor: 4.280

Review 4.  Social and psychological impact of the COVID-19 pandemic on people with Parkinson's disease: a scoping review.

Authors:  S K Brooks; D Weston; N Greenberg
Journal:  Public Health       Date:  2021-09-01       Impact factor: 4.984

Review 5.  The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view.

Authors:  Nastaran Sabetkish; Alireza Rahmani
Journal:  Health Sci Rep       Date:  2021-10-01

Review 6.  New Recovery Strategies in Motor and Cognitive Functions, before, during and after Home-Confinement COVID-19, for Healthy Adults and Patients with Neurodegenerative Diseases: Review.

Authors:  Manuela Bacanoiu; Mircea Danoiu; Mihnea Marin; Mihai Robert Rusu; Ligia Rusu
Journal:  J Clin Med       Date:  2022-01-25       Impact factor: 4.241

7.  Changes in non-motor symptoms in patients with Parkinson's disease following COVID-19 pandemic restrictions: A systematic review.

Authors:  Francesca Mameli; Eleonora Zirone; Benedetta Capetti; Denise Mellace; Roberta Ferrucci; Giulia Franco; Alessio Di Fonzo; Sergio Barbieri; Fabiana Ruggiero
Journal:  Front Psychol       Date:  2022-07-22

8.  Impact of COVID-19 Pandemic on (Health) Care Situation of People with Parkinson's Disease in Germany (Care4PD).

Authors:  Odette Fründt; Anne-Marie Hanff; Tobias Mai; Christiane Kirchner; Emma Bouzanne des Mazery; Ali Amouzandeh; Carsten Buhmann; Rejko Krüger; Martin Südmeyer
Journal:  Brain Sci       Date:  2021-12-31

9.  Secondary Impact of COVID-19 Pandemic on People with Parkinson's Disease-Results of a Polish Online Survey.

Authors:  Karolina Krzysztoń; Beata Mielańczuk-Lubecka; Jakub Stolarski; Anna Poznańska; Katarzyna Kępczyńska; Agata Zdrowowicz; Izabela Domitrz; Jan Kochanowski
Journal:  Brain Sci       Date:  2021-12-26

Review 10.  Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?

Authors:  Lea Krey; Meret Koroni Huber; Günter U Höglinger; Florian Wegner
Journal:  Brain Sci       Date:  2021-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.